Meeting
2019 Gastrointestinal Cancers Symposium
Subgroup analysis of JCOG0501 phase III study to confirm superiority of additional neoadjuvant chemotherapy with S-1 plus cisplatin to D2 gastrectomy with S-1 adjuvant chemotherapy for resectable type IV or large type III gastric cancer.
Authors
Hitoshi Katai
National Cancer Center Hospital, Tokyo, Japan
Hitoshi Katai , Yoshiaki Iwasaki , Masanori Terashima , Junki Mizusawa , Hiroshi Katayama , Kenichi Nakamura , Takaki Yoshikawa , Narikazu Boku , Takanobu Yamada , Tsuneaki Fujiya , Yoshiyuki Kawashima , Takahiro Kinoshita , Manabu Ohashi , Hiroki Yamaue , Takeshi Sano , Mitsuru Sasako
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
UMIN000000279
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 110)
DOI
10.1200/JCO.2019.37.4_suppl.110
Abstract #
110
Poster Bd #
K2
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).
First Author: Izuma Nakayama
Poster
2020 ASCO Virtual Scientific Program
Checkmate 77T: A phase III trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant nivo in resectable early-stage NSCLC.
First Author: Tina Cascone
Poster
2018 ASCO Annual Meeting
Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer: Japan Clinical Oncology Group study (JCOG0501).
First Author: Yoshiaki Iwasaki
Poster
2017 ASCO Annual Meeting
Phase III trial to evaluate the efficacy of neoadjuvant chemotherapy with S-1 plus oxaliplatin followed by D2 gastrectomy with adjuvant S-1 in locally advanced gastric cancer: Japan Clinical Oncology Group study JCOG1509 (NAGISA trial).
First Author: Masanori Tokunaga